Description
Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer (LAPC).
The study is a multi-center, un-blinded, randomized control study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Location: SIMR (Sacramento/Valley Area)
Please contact: SIMR@sutterhealth.org about TIGeR-PaC Study
Principal Investigator
Co-Investigator(s)
Jasdeepa Nagi, M.D., Sivakumar Reddy, M.D., Vijay Suhag, M.D., Benjamin Coombs, D.O., Deepti Behl, MD, Anthony T Pu, Radiation Oncologist, Aria Sasaki, M.D., Christopher Jones, MD, Brian K. Kim, M.D, Hubert Y Pan, Radiation Oncologist, Charlotte D Kubicky, Radiation Oncologist, Henal Patel, M.D., Carlin R Hauck, Radiation Oncologist
Funder
RenovoRx